Skip to main content
Egyptian Rheumatology and Rehabilitation

Table 1 Comparison between patient group (symptomatic and asymptomatic sides) and control group regarding different parameters of spinal accessory nerve motor conduction study

From: Spinal accessory neuropathy in patients with chronic trapezius myofascial pain syndrome

Spinal accessory nerve motor conduction study parameters

Patient group (symptomatic side) (n = 25)

Patient group (asymptomatic side) (n = 25)

Control group (n = 20)

Test of significance

P

CMAP latency (ms)

 Median

2.50

2.40

2.15

K = 13.640

0.001*

 Mean ± SD

2.53 ± 0.37

2.26 ± 0.28

2.16 ± 0.25

  

 Min.–Max.

1.8–3.4

1.6–2.6

1.8–2.7

  

 Test of significance

Z1 = − 2.453

Z2 = − 1.554

Z3 = − 3.475

  

P

P1= 0.014*†

P2 = 0.120‡

P3 = 0.001*§

  

CMAP amplitude (mV)

 Median

12.00

14.50

12.55

K = 3.809

0.149

 Mean ± SD

12.46 ± 4.95

14.92 ± 4.84

13.41 ± 2.89

  

 Min.–Max.

4.8–24.5

8.0–23.5

9.2–20.2

  

 Test of significance

Z1 = – 1.854

Z2 = − 0.891

Z3 = − 1.143

  

P

P1 = 0.064†

P2 = 0.373‡

P3 = 0.253§

  
  1. CMAP compound muscle action potential, SD standard deviation, Min. minimal value, Max. maximal value, n number of subjects, Z1 value of Mann-Whitney test for comparing between patient group (symptomatic side) versus patient group (asymptomatic side), Z2 value of Mann-Whitney test for comparing between patient group (asymptomatic side) versus control group, Z3 value of Mann-Whitney test for comparing between patient group (symptomatic side) versus control group, K value of Kruskal-Wallis test for comparing between the three groups
  2. *Statistically significant at P < 0.05
  3. †P1 value for comparing between patient group (symptomatic side) and patient group (asymptomatic side)
  4. ‡P2 value for comparing between patient group (asymptomatic side) and control group
  5. §P3 value for comparing between patient group (symptomatic side) and control group
Back to article page